Kemwell Biopharma

Antibody or immunoglobulin is a protective protein which is produced by the immune system in response to a foreign body or antigen. These antibodies recognise the antigen and neutralise it by phagocytosis. A wide range of substances can act as antigens including the disease-causing pathogen and other toxic materials like insect venom. Currently, medicine has evolved into a new era of personalised therapy. It has led to  Monoclonal Antibody Development   (mAb) which can treat a wide range of diseases.                   Monoclonal antibodies develop  from identical immune cells which are all clones of a unique parent cell. They show monovalent affinity in recognising the antigen. Since the first licensing of the monoclonal antibodies 34 years ago, its market has seen exponential development in the last few years. Now they used to treat a wide range of diseases like cancer, arthritis, multiple sclerosis and heart d...

It was the mid-1990s, when pharmaceutical companies began developing their own versions of medical products. It was unregulated and unheard of at the time, but a steadily growing trend. Comprehensive guidelines were only laid down between 2005 – 2006 by the EU. Not long after, the WHO followed suit and finalised a more consistent set of guidelines for Biosimilars Manufacturing . And thus, began the mainstream prevalence of Biosimilars around the world. Biosimilars are basically ‘approved’ replicas of innovator biologic products, made by different companies. Biologic medical products are mostly made via DNA recombination technology and comprise of highly complex molecular structures as opposed to normal generic drugs. Normally, they are responsive and highly sensitive to changes in the manufacturing environment. Therefore, the Biopharmaceutical product development process must be able to fully replicate the properties of the innovator product, in order to be available in...

Monoclonal Antibody Development is the recent topic of debate in the medical scenario. Monoclonal Antibodies, often referred to as mAbs, are a proven effective therapeutic modality in human malignancy. Minute structures of Mabs doesn’t allow it to be seen by the naked eye. They are laboratory-produced antibodies derived from the millions of antibodies which the body makes every day to fight foreign invaders. Since their inception, Mabs have radically transformed understandings about the pathways of disease. Significance of Monoclonal Antibodies Fights Cancer Cells   Mabs specifically target cancer cells while retaining healthy ones. This medical method means fewer side effects than conventional chemotherapy or radiotherapy. In addition to this, Mabs provide an important tool to harness the body’s own immune system t fight cancer, called Immunotherapy. Treatment of chronic inflammatory and Autoimmune Diseases Mabs have not only been successful towards cancer ce...